Incidence of vaccine reactogenicity within 14 days of receipt of vaccine

SymptomNo. of subjects with symptom/total no. of subjects
Cohort 1 (0.01 μg)Cohort 2 (0.1 μg)Cohort 3 (0.5 μg)Cohort 4 (2.5 μg)Cohort 5 (10 μg)Cohort 6 (20 μg)Cohort 7Totala
First 20-μg doseSecond 20-μg dose
Local symptoms
Systemic symptoms
  • a Reactogenicity in the two-dose cohort was not counted twice if a person experienced the same symptom after both vaccinations.